GlassScriptPhysician profile
Megan E Morgenthaler
NPI 1922734383
$1,360.62
in general payments reported to CMS, 2019-2025
10 companies · $110 in 2025
The $110 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $59.08 · 2024: $1,192 · 2025: $110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,361.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,360.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $255.16 | 2023-2024 | |
| Axsome Therapeutics, INC. | $246.80 | 2024 | Auvelity |
| Amgen INC. | $132.12 | 2024 | Repatha |
| Kyowa Kirin, INC. | $121.81 | 2024 | Crysvita |
| Genzyme Corporation | $117.14 | 2024 | |
| Abbott Laboratories | $110.60 | 2024 | Freestyle Libre 3 |
| Tris Pharma INC | $109.85 | 2025 | Dyanavel Xr, Quillichew Er, Quillivant |
| Exeltis, USA INC. | $101.69 | 2024 | Slynd |
| Astrazeneca Pharmaceuticals LP | $95.25 | 2024 | Breztri |
| Teva Pharmaceuticals USA, INC. | $70.20 | 2024 | Austedo Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Morgenthaler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.